Search

Displaying results 2371 - 2380 of 4234 in total
  1. Drug

    ACR-16

    go.drugbank.com/drugs/DB05371
    Investigational

    ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington

  2. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.

  3. Drug

    Phosphatidyl serine

    go.drugbank.com/drugs/DB00144
    ApprovedNutraceutical

    Because of the potentail cognitive benefits of phosphatidylserine, the substance is sold as a dietary supplement to people who believe they can benefit from an increased intake.

  4. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. A new drug application (NDA) was filed with the FDA in 2011, however, the seco...

  5. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). By substituting the native manganese cofactor with...

  6. Drug

    Suramin

    go.drugbank.com/drugs/DB04786
    Investigational

    Suramin is manufactured by Bayer in Germany as Germanin®.

  7. Drug

    Delorazepam

    go.drugbank.com/drugs/DB01511
    IllicitInvestigational

    It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam.

  8. Drug

    Rolicyclidine

    go.drugbank.com/drugs/DB01549
    ExperimentalIllicit

    Rolicyclidine (PCPy) is classified as a dissociative anesthetic agent. It also has hallucinogenic and sedative properties.

  9. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    Simeprevir was approved by the FDA in November 2014 and is marketed under the brand name Olysio as oral tablets. … Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and [DB05521] but is classified as a second generation protease inhibitor.

  10. Drug

    Pegloxenatide

    go.drugbank.com/drugs/DB19230
    Investigational

    Pegloxenatide is under investigation in clinical trial NCT05172999 (Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia).